Brain Chemistry Labs, The Institute for Ethnomedicine, Suite 3, 1130 S Highway 89, Jackson, WY, USA.
Neurotox Res. 2021 Feb;39(1):17-26. doi: 10.1007/s12640-020-00168-2. Epub 2020 Apr 2.
L-serine is a naturally occurring dietary amino acid that has recently received renewed attention as a potential therapy for the treatment of amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), hereditary sensory autonomic neuropathy type I (HSAN1), and sleep induction and maintenance. We have previously reported L-serine functions as a competitive inhibitor of L-BMAA toxicity in cell cultures and have since progressed to examine the neuroprotective effects of L-serine independent of L-BMAA-induced neurotoxicity. For example, in a Phase I, FDA-approved human clinical trial of 20 ALS patients, our lab reported 30 g L-serine/day was safe, well-tolerated, and slowed the progression of the disease in a group of 5 patients. Despite increasing evidence for L-serine being useful in the clinic, little is known about the mechanism of action of the observed neuroprotection. We have previously reported, in SH-SY5Y cell cultures, that L-serine alone can dysregulate the unfolded protein response (UPR) and increase the translation of the chaperone protein disulfide isomerase (PDI), and these mechanisms may contribute to the clearance of mis- or unfolded proteins. Here, we further explore the pathways involved in protein clearance when L-serine is present in low and high concentrations in cell culture. We incubated SH-SY5Y cells in the presence and absence of L-serine and measured changes in the activity of proteolytic enzymes from the autophagic-lysosomal system, cathepsin B, cathepsin L, and arylsulfatase and specific activities of the proteasome, peptidylglutamyl-peptide hydrolyzing (PGPH) (also called caspase-like), chymotrypsin, and trypsin-like. Under our conditions, we report that L-serine selectively induced the activity of autophagic-lysosomal enzymes, cathepsins B and L, but not any of the proteasome-hydrolyzing activities. To enable comparison with previous work, we also incubated cells with L-BMAA and report no effect on the activity of the autophagic lysosomes or the proteasomes. We also developed an open-source script for the automation of linear regression calculations of kinetic data. Autophagy impairment or failure is characteristic of many neurodegenerative disease; thus, activation of autophagic-lysosomal proteolysis may contribute to the neuroprotective effect of L-serine, which has been reported in cell culture and human clinical trials.
L-丝氨酸是一种天然存在的膳食氨基酸,最近作为治疗肌萎缩侧索硬化症 (ALS)、阿尔茨海默病 (AD)、遗传性感觉自主神经病 I 型 (HSAN1) 以及诱导和维持睡眠的潜在疗法重新受到关注。我们之前的研究表明,L-丝氨酸在细胞培养物中作为 L-BMAA 毒性的竞争性抑制剂发挥作用,此后我们进一步研究了 L-丝氨酸的神经保护作用,而不考虑 L-BMAA 诱导的神经毒性。例如,在一项针对 20 名 ALS 患者的 I 期、FDA 批准的人体临床试验中,我们实验室报告称,每天 30g L-丝氨酸是安全的、耐受良好的,并且可以减缓 5 名患者的疾病进展。尽管越来越多的证据表明 L-丝氨酸在临床上有用,但对于观察到的神经保护作用的机制知之甚少。我们之前在 SH-SY5Y 细胞培养物中报道称,L-丝氨酸本身可以使未折叠蛋白反应 (UPR) 失调并增加伴侣蛋白二硫异构酶 (PDI) 的翻译,这些机制可能有助于清除错误折叠或未折叠的蛋白质。在这里,我们进一步研究了当 L-丝氨酸在细胞培养物中存在低浓度和高浓度时参与蛋白质清除的途径。我们在存在和不存在 L-丝氨酸的情况下孵育 SH-SY5Y 细胞,并测量自噬溶酶体系统中蛋白酶的活性变化、组织蛋白酶 B、组织蛋白酶 L 和芳基硫酸酯酶以及蛋白酶体的比活性、肽谷氨酰肽水解 (PGPH)(也称为半胱天冬酶样)、糜蛋白酶和胰蛋白酶样。在我们的条件下,我们报告 L-丝氨酸选择性诱导自噬溶酶体酶、组织蛋白酶 B 和 L 的活性,但不影响蛋白酶体水解活性。为了与以前的工作进行比较,我们还将细胞与 L-BMAA 孵育,并报告自噬溶酶体或蛋白酶体的活性没有变化。我们还开发了一个用于自动执行动力学数据线性回归计算的开源脚本。自噬受损或失败是许多神经退行性疾病的特征;因此,自噬溶酶体蛋白水解的激活可能有助于 L-丝氨酸的神经保护作用,这在细胞培养和人体临床试验中都有报道。